Xencor Inc (FRA:XE9)
€ 23.4 0.4 (1.74%) Market Cap: 1.63 Bil Enterprise Value: 1.19 Bil PE Ratio: 0 PB Ratio: 2.35 GF Score: 59/100

Xencor Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 10, 2021 / 07:25PM GMT
Release Date Price: €37.2 (-2.11%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

Great. Thank you so much. Good afternoon and good morning depending on where you are in the world. Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech equity analysts at Barclays. I just want to thank everybody for taking time out of the day today. If you've got questions, do ping me at [email protected] or get me on Bloomberg.

It gives me great pleasure to introduce the management team from Xencor. And we have Bassil Dahiyat with us, CEO. We've also got Charles from IR with us as well.

Questions & Answers

Peter Richard Lawson;Bassil I. Dahiyat
Barclays Bank PLC, Research Division - Research Analyst;Xencor, Inc. - Co-Founder, CEO, President &

And just to start the ball rolling with questions. I've been asking most of my companies this, just the -- where you view Xencor's kind of point of differentiation in the oncology space and kind of the core competencies of the company?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot